- Home
- EWTX vs FRME Comparison
EWTX vs FRME Comparison
Compare EWTX & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EWTX | FRME |
|---|---|---|
| Founded | 2017 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EWTX | FRME |
|---|---|---|
| Price | $28.57 | $41.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $34.71 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 1.1M | 353.1K |
| Earning Date | 03-02-2026 | 01-26-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 3.88 |
| Revenue | N/A | ★ $641,697,000.00 |
| Revenue This Year | N/A | $23.68 |
| Revenue Next Year | N/A | $8.93 |
| P/E Ratio | ★ N/A | $10.52 |
| Revenue Growth | N/A | ★ 5.03 |
| 52 Week Low | $10.60 | $33.13 |
| 52 Week High | $30.48 | $45.62 |
Technical Indicators
Market Signals| Indicator | EWTX | FRME |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 69.75 |
| Support Level | $27.07 | $37.73 |
| Resistance Level | $29.98 | $40.24 |
| Average True Range (ATR) | 1.54 | 1.07 |
| MACD | -0.06 | 0.35 |
| Stochastic Oscillator | 61.43 | 95.68 |
Price Performance
Historical ComparisonAbout EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.